Search
Now showing items 11-20 of 48
Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer.
(MDPI, 2021-05-10)
Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in ...
A mouse SWATH-mass spectrometry reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts.
(COMPANY BIOLOGISTS LTD, 2020-06-03)
SWATH-mass spectrometry (MS) enables accurate and reproducible proteomic profiling in multiple model organisms including the mouse. Here, we present a comprehensive mouse reference spectral library (MouseRefSWATH) that ...
Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
(FUTURE MEDICINE LTD, 2020-08-01)
Gastrointestinal stromal tumors (GIST) can be molecularly classified based on different subtypes including mutations in KIT and PDGFRA. Patients with PDGFRA mutations are an important subgroup that commonly arise in the ...
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
(LIPPINCOTT WILLIAMS & WILKINS, 2020-06-05)
PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ...
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
(MDPI, 2020-05-01)
Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. ...
Future Directions in the Treatment of Osteosarcoma.
(MDPI, 2021-01-15)
Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy ...
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer.
(DOVE MEDICAL PRESS LTD, 2021-03-08)
Insertion mutations in exon 20 (Ex20ins) of the epidermal growth factor receptor (EGFR) gene are the largest class of EGFR mutations in non-small cell lung cancer (NSCLC) for which there are currently no approved targeted ...
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
(NATURE PORTFOLIO, 2021-03-05)
Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised ...
Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.
(ELSEVIER SCIENCE INC, 2021-03-01)
Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients ...
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2021-02-15)
Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ...